[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.157.19.94. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Letters
July 10, 2002

Safety and Tolerability of Intermittent Rifampin/Pyrazinamide for the Treatment of Latent Tuberculosis Infection in Prisoners

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthor

JAMA. 2002;288(2):165-166. doi:10.1001/jama.288.2.162

To the Editor: Two months of treatment with rifampin and pyrazinamide is effective in preventing tuberculosis (TB) in tuberculin-positive, human immunodeficiency virus (HIV)-seropositive individuals.1,2 Recent reports, however, have raised concerns about the safety of rifampin and pyrazinamide for latent TB infection in HIV-seronegative individuals, although toxicity incidence is not known.3 The reported adverse events have occurred with use of a daily regimen. We studied the outcomes of a twice-weekly regimen of these medications to treat latent TB in 600 prison inmates in Maryland.

First Page Preview View Large
First page PDF preview
First page PDF preview
×